Positron Emission Tomography (PET) quantification of GABAA receptors in the brain of fragile X patients

11Citations
Citations of this article
37Readers
Mendeley users who have this article in their library.

Abstract

© 2015 D'Hulst et al.Over the last several years, evidence has accumulated that the GABAA receptor is compromised in animal models for fragile X syndrome (FXS), a common hereditary form of intellectual disability. In mouse and fly models, agonists of the GABAA receptor were able to rescue specific consequences of the fragile X mutation. Here, we imaged and quantified GABAA receptors in vivo in brain of fragile X patients using Positron Emission Topography (PET) and [11C]flumazenil, a known high-affinity and specific ligand for the benzodiazepine site of GABAA receptors. We measured regional GABAA receptor availability in 10 fragile X patients and 10 control subjects.We found a significant reduction of on average 10% in GABAA receptor binding potential throughout the brain in fragile X patients. In the thalamus, the brain region showing the largest difference, the GABAA receptor availability was even reduced with 17%. This is one of the first reports of a PET study of human fragile X brain and directly demonstrates that the GABAA receptor availability is reduced in fragile X patients. The study reinforces previous hypotheses that the GABAA receptor is a potential target for rational pharmacological treatment of fragile X syndrome.

Cite

CITATION STYLE

APA

D’Hulst, C., Heulens, I., Van Der Aa, N., Goffin, K., Koole, M., Porke, K., … Kooy, R. F. (2015). Positron Emission Tomography (PET) quantification of GABAA receptors in the brain of fragile X patients. PLoS ONE, 10(7). https://doi.org/10.1371/journal.pone.0131486

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free